Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Burning Rock Partners with CStone for RET Companion Diagnostic

publication date: Jun 29, 2020

Burning Rock, a Guangzhou biotech, partnered with CStone Pharma to co-develop and commercialize companion diagnostics to detect RET alterations in cancer patients. Suzhou's CStone is developing pralsetinib in China for cancers caused by RET mutations, especially non-small cell lung cancer (NSCLC). Burning Rock specializes in Next-Gen Sequencing for precision oncology. The company has developed 32 tests for different cancer types and has labs in Beijing, Shanghai and Guangzhou. More details....

Stock Symbols: (NSDQ: BNR) (HK: 2616)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China